This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Irene Weitzman, PhD

Arch Dermatol. 1986;122(10):1161-1168.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Significant advances made in recent years in the treatment of neoplastic disease and the prevention of organ graft rejection have been accompanied by an increase in opportunistic infections.¹ Although bacteria still account for most of these infections, the incidence of fungal infections in such patients is rising.^1-4 This assault on the immune system by immunosuppressive therapy, including systemic corticosteroids, cytotoxic and antineoplastic drugs, and irradiation with roentgen rays, renders the host susceptible to fungi that normally do not pose a threat to patients with intact immunologic defense mechanisms.^1,3 Depletion of the number of neutrophils, defects in neutrophil function, and T-cell defects also predispose the host to fungal infections.³

Although species of Candida and Aspergillus as well as Cryptococcus neoformans and members of the Zygomycetes (Phycomycetes) remain the most common fungal pathogens in the compromised host,² other more unusual fungal infections are being caused by fungi . . . [Full Text PDF of this Article]

Author Affiliations
From the Bureau of Laboratories, Department of Health, The City of New York.

Footnotes
Accepted for publication May 6, 1986.

Reprint requests to the Bureau of Laboratories, Department of Health, The City of New York, 455 First Ave, New York, NY 10016 (Dr Weitzman).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?